Data from the PARTIQoL trial show no significant difference in progression-free survival, bowel function, and other patient quality-of-life measures between PBT and IMRT.
ASTRO Annual Meeting
A late-breaking abstract at ASTRO 2024 shows local therapy history does not significantly affect the risk of death in patients with mCRPC receiving an ARPI.
Advertisement
New CEASAR findings at ASTRO 2024 show how 3 treatment modalities differ in prostate cancer patient functioning—as well as how patients perceive the issues.
Ga-68 PSMA-11 radiotracer may be a feasible option for SCINTIX radiation therapy in patients whose prostate cancer has spread to the bones.
Follow-up phase 3 analyses support a hypofractionated radiation therapy regimen to conventional dosing in patients with prostate cancer.
Advertisement
Advertisement
Advertisement
Trending on Urology Times
1
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
2
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
3
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5